RICHMOND, Va.--(BUSINESS WIRE)--June 9, 2006--Insmed, Inc (NASDAQ: INSM - News) today provided an update on the launch of IPLEX (mecasermin rinfabate (rDNA origin) injection) and the Company’s payer Utilization Program for the treatment of patients with severe short stature associated with severe primary IGF-I deficiency (Primary IGFD).
